SIPULEUCEL-T

Sipuleucel-T Clinical Trials

Dendreon currently has ongoing Phase 2 PHASE 2 CLINICAL TRIALA study to assess the preliminary efficacy of a treatment at the dose and dosing schedule determined in the Phase 1 trial and to provide further safety information(for example, whether it shrinks a tumor or improves blood test results).Close and Phase 3 PHASE 3 CLINICAL TRIALA study to compare the results of people taking a new treatment with the results of people taking the standard treatment (for example, which group has better survival rates or fewer side effects). In most cases, studies move into Phase 3 only after a treatment seems to work in Phase 2. Phase 3 trials may include hundreds of people.Close studies in early and advanced prostate cancer.

P10-1

  • An Open-Label, Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated with Sipuleucel-T on Dendreon Study P-11
  • To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P10-2

  • A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Non-Metastatic Prostate Cancer and a Rising Prostate Specific Antigen After Primary Therapy
  • To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P10-3 (called PROCEED)

  • A Registry of Sipuleucel-T in Men with Advanced Prostate Cancer (called PROCEED) to Further Evaluate Safety and Survival Associated with Sipuleucel-T
  • To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P11-1

  • An Open-Label Study of Sipuleucel-T in European Men with Metastatic, Castrate Resistant Prostate Cancer
  • To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P11-3

  • A Randomized, Open-Label, Phase 2 Trial of Sipuleucel-T with Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men with Metastatic Castrate Resistant Prostate Cancer
  • To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P12-1

  • An Observational Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Metastatic Disease in Castrate-Resistant Prostate Cancer
  • To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P12-2

  • A Randomized, Open-Label, Phase 2 Trial Examining Combination Therapy with Sipuleucel-T and Enzalutamide in Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer.
  • To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

This list may not be fully up to date. For current status and more information on our ongoing clinical trials, please visit http://www.clinicaltrials.gov.